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Background 
• Anticoagulation (AC) is required in various conditions: 
DVT Prophylaxis (Orthopedic Surgery), NVAF (to reduce 
stroke risk), DVT or PE Treatment 
• AC may be assured using: heparins, VKAs and NOACs 
• Interesting for PNHS: costs increased 0.8% and AC 
represent the 3rd FT group with greater weight (7.7%; 84 
M€; ∆ 27.7%)(1) 
 
1. INFARMED, Direção de Informação e Planeamento Estratégico. Monitorização mensal do consumo de medicamentos no 
ambulatório do SNS. Janeiro-Novembro 2016. 
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Objectives 
• This study analyses the utilisation patterns of 
AC in Portugal, in the outpatient market, 
considering national, regional and 
international asymmetries.  
• It also analyses the evolution of costs (for the 
PNHS and for patients) and the costs of 
treatment per day.  
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Methods 
• Descriptive study considering a 10 year-period (2006 to 2015) 
• Outpatient sales data obtained from INFARMED to characterise AC use.  
• Data treated annually and disaggregated by the 18 districts of Portugal, considering 
ATC classification (B01A Antithrombotic Agents) and respective DDDs.(1)   
• Utilisation indicators used: DDDs, DID (DDDs/1000 inhabitants/day), considering the 
mean annual resident population in mainland Portugal(2) and the ratio of NOACs on 
the total market of ACs.  
• Cost indicators used: total costs, PNHS costs, out-of-pocket (OOP) costs and costs of 
treatment per day (CTD).  
 
1. WHO Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical (ATC) classification index 
with defined Daily Doses (DDDs). 2. INE, 2016. População média anaula residente (Nº) por local de residência 
(Distrito/Região); Anual – INE. Estimativas Anuais da População Residente. 
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Total anticoagulant market = apixaban + dabigatran + rivaroxaban + warfarin + heparins ( fractionated + unfractionated) + fondaparinux ** MAT: 
Moving Annual Total – the total over the previous 12 months *** Days on therapy are based on IMS Standard Units data converted using Average 
Daily Dose assumptions based on IMS Medical Audit Data & BMS/Pfizer Alliance assumptions 
http://www.abpi.org.uk/media-centre/newsreleases/2016/Documents/Embargo9May_ABPI_OneYearOn_FINALREPORT.pdf 
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Results: % Ratio of NOACs on total AC 
market international comparison 
Source: adapted from IMS,  2015   
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% Ratio of NOACs on total AC market in mainland Portugal 
(PNHS) by district and region, in packages (2015) 
 
Source: own development, INFARMED data 
Region Ratio 2015 
North 24.8% 
Center 40.1% 
LVT 43.3% 
Alentejo 33.7% 
Algarve 46.1% 
 Mainland Portugal  35.9% 
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Year 2006: DID Total PNHS 4,28 Year 2015: DID Total PNHS 17,03  
Região Distrito 2006 2015 Var 
North Braga 5,77 16,32 183% 
North Bragança 3,52 19,81 464% 
North Porto 4,81 15,07 213% 
North 
Viana do 
Castelo 7,27 21,20 192% 
North Vila Real 4,77 19,76 314% 
Center Aveiro 4,32 17,79 312% 
Center Castelo Branco 4,29 22,88 433% 
Center Coimbra 3,86 26,51 587% 
Center Guarda 3,48 19,56 462% 
Center Leiria 3,65 17,62 383% 
Center Viseu 3,62 21,69 499% 
LVT Lisboa 3,90 16,02 311% 
LVT Santarém 4,01 17,57 338% 
LVT Setúbal 3,60 14,96 315% 
Alentejo Beja 2,23 11,55 418% 
Alentejo Évora 5,30 20,03 278% 
Alentejo Portalegre 3,21 14,76 360% 
Algarve Faro 3,50 14,12 303% 
TOTAL PNHS 4,28 17,03 298% 
Results: Costs 
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Discussion & Conclusion: Potential 
influence of guidelines on drug use 
Norm 26/2012 
Recommend. ESC FA (2012) 
Recomend ESC AF (2016) 
ACSS contract terms (2016) 
Recommend ESC APE 2014) 
Recommend. ESC ACS-NSTE (2015) 
Bulletin ARS LVT, 2013 
Year 
DID 
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Thank you for your attention! 
